AbCheck is developing novel approaches beyond antibody-antigen binding affinity criteria for the discovery of therapeutic mAbs with challenging Target Product Profiles (TPPs).
In this context, we have developed a microfluidics-based, function-oriented method for efficient discovery of antibodies with distinct modalities:
Regular binders to recombinant purified antigens, native membrane targets and VLPs
Narrow specificity binders to mutant forms of antigens, specific epitopes or protein orthologues
Functional antibodies, e.g. triggering internalization or activation of targets
Key
Advantages
- High throughput of microfluidics (millions of droplets/day)
- Enables sampling from unbiased immunized repertoires in contrast to library-based technologies
- Reduced risk of losing precious mAbs by direct sorting for desired properties (function or rare specificity)
- Process enables determining functional leads in ~3-4 months
- Efficient functional sorting, e.g. for agonists against GPCRs or internalizing antibodies for ADC development; can be combined with other selection criteria
- Combination of microfluidics/dual staining identifies binders with rare specificity, resulting in detection of mAbs with extremely high specificity and affinity
- Combination of microfluidics with proprietary transgenic rabbit model demonstrates easy and efficient way of generating highly specific high-affinity antibodies to MHC-I-peptide complexes
ABCHECK’S NOVEL MICROFLUIDICS PLATFORM
Technology Overview
ABCHECK’S NOVEL MICROFLUIDICS PLATFORM
